Pharma merger and acquisitions... Jul 15
Colorcon will collaborate with i2O to accelerate i2O’s research and development efforts... Dec 04
Teplizumab, Provention Bio’s lead drug candidate, is an anti-CD3 monoclonal antibody (mAb) being developed for the delay or prevention of type 1 diabetes ... Aug 29
Children diagnosed with type 1 diabetes under the age of seven have a different form of the condition than those aged 13 or over, research ... Mar 18
-Advertisements-